Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.
Eli Lilly and Company and Lycia Therapeutics, Inc. announced on 25 August a multi-year research collaboration and licensing agreement for Lilly to use Lycia’s proprietary lysosomal targeting chimera (LYTAC) protein degradation technology. South San Francisco-based Lycia gets $35m up front and could earn up to $1
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?